Drug intelligence / Profile preview

Quercus nigra pollen

Development stage: Unknown
Modality: Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Intradermal, Subcutaneous, Sublingual, Intranasal, Ophthalmic

Overview

Quercus nigra pollen is an extract used in allergy testing. It is derived from the pollen of the water oak tree (Quercus nigra) and is primarily used for diagnosing and treating allergies related to this specific pollen. The mechanism of action involves inducing an immune response to desensitize individuals against the allergen.

Other names: quercus nigra pollen

Targets

BCR (Immunoglobulin G B Cell Receptor)TCR (T cell antigen receptor complex)

Beyond the preview

Go deeper on Quercus nigra pollen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quercus nigra pollen.

Explore the full profile